KTRA
Income statement / Annual
Last year (2025), Kintara Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Kintara Therapeutics, Inc.'s net income was -$22.65 B.
See Kintara Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$55.00 K
|
$60.00 K
|
$60.00 K
|
$32.00 K
|
$10.00 K
|
$16.35 K
|
$24.53 K
|
$16.68 K
|
$10.29 K
|
| Gross Profit |
$0.00
|
-$55.00 K
|
-$60.00 K
|
-$60.00 K
|
-$32.00 K
|
-$10.00 K
|
-$16.35 K
|
-$24.53 K
|
-$16.68 K
|
-$10.29 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$13.34 B
|
$2.66 M
|
$9.31 M
|
$15.17 M
|
$11.82 M
|
$3.63 M
|
$3.66 M
|
$7.13 M
|
$5.00 M
|
$3.36 M
|
| General & Administrative Expenses |
$4.31 B
|
$5.79 M
|
$5.49 M
|
$7.51 M
|
$9.76 M
|
$4.51 M
|
$4.74 M
|
$4.04 M
|
$3.32 M
|
$2.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.31 B
|
$5.79 M
|
$5.49 M
|
$7.51 M
|
$9.76 M
|
$4.51 M
|
$4.74 M
|
$4.04 M
|
$3.32 M
|
$2.85 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$17.65 B
|
$8.45 M
|
$14.80 M
|
$22.68 M
|
$21.57 M
|
$8.14 M
|
$8.40 M
|
$11.17 M
|
$8.32 M
|
$6.21 M
|
| Cost And Expenses |
$0.00
|
$8.45 M
|
$14.80 M
|
$22.68 M
|
$21.57 M
|
$8.14 M
|
$8.40 M
|
$11.17 M
|
$8.32 M
|
$6.21 M
|
| Interest Income |
$361.63 M
|
$0.00
|
$137.00 K
|
$14.00 K
|
$120.00
|
$75.25 K
|
$60.70 K
|
$33.24 K
|
$457.00
|
$108.00
|
| Interest Expense |
$4.14 B
|
$0.00
|
$0.00
|
$14.00 K
|
$26.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$55.00 K
|
$60.00 K
|
$60.00 K
|
$32.00 K
|
$10.00 K
|
$16.35 K
|
$24.53 K
|
$16.68 K
|
$10.29 K
|
| EBITDA |
$0.00 |
-$8.40 M |
-$14.59 M |
-$22.62 M |
-$38.15 M |
-$9.12 M |
-$8.03 M |
-$11.11 M |
-$8.07 M |
-$8.85 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
$131.00 K
|
$147.00 K
|
$21.00 K
|
-$16.63 M
|
-$982.00 K
|
$350.28 K
|
$36.35 K
|
$324.16 K
|
-$2.27 M
|
| Income Before Tax |
-$22.65 B
|
-$8.32 M
|
-$14.65 M
|
-$22.66 M
|
-$38.30 M
|
-$9.13 M
|
-$8.05 M
|
-$11.14 M
|
-$8.08 M
|
-$8.86 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$981.37 K
|
-$639.85 K
|
-$39.46 K
|
-$477.67 K
|
$5.30 M
|
| Net Income |
-$22.65 B
|
-$8.50 M
|
-$14.65 M
|
-$22.66 M
|
-$38.32 M
|
-$10.11 M
|
-$7.41 M
|
-$11.14 M
|
-$8.08 M
|
-$8.86 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.21 |
-3.23 |
-9.27 |
-25.8 |
-74.02 |
-48.39 |
-143.87 |
-266.96 |
-335.43 |
-404.86 |
| EPS Diluted |
-1.21 |
-3.23 |
-9.27 |
-25.8 |
-74.02 |
-48.39 |
-143.87 |
-266.96 |
-335.43 |
-404.86 |
| Weighted Average Shares Out |
$18.66 M
|
$2.64 M
|
$1.62 M
|
$974.04 K
|
$517.72 K
|
$208.88 K
|
$51.49 K
|
$41.72 K
|
$24.09 K
|
$21.90 K
|
| Weighted Average Shares Out Diluted |
$18.66 M
|
$2.64 M
|
$1.62 M
|
$974.00 K
|
$517.72 K
|
$208.88 K
|
$51.49 K
|
$41.72 K
|
$24.09 K
|
$21.90 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
